BUSINESS
Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
January 31, 2023
Shionogi delivered sharp revenue growth and record profits in April-December 2022 as it hauled in sales of 100 billion yen from the government purchase of its COVID-19 pill Xocova (ensitrelvir), according to its earnings released…

LATEST

January 31, 2023
Nippon Boehringer Ingelheim said on January 30 that it has concluded an AI-based research collaboration agreement with Jichi Medical University and its spinout DeepEyeVision to explore effective therapeutic methods for dry age-related macular degeneration (AMD) in Japan.Under the pact, the…
January 31, 2023
Following a major reorganization last year, the Ministry of Health, Labor and Welfare’s (MHLW) Health Policy Bureau is expected to add more personnel to fortify a structure for executing administrative functions to fuel pharma industry…
January 31, 2023
Bristol Myers Squibb has forged a strategic alliance with Kyoto University to drive the creation of innovative medicines, making it the second Japanese institution to join the company’s global research collaboration initiative, dubbed GECI.The Japan unit of BMS announced the…

Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

By Eric Persoff

The advance of cell therapy is one of the most exciting innovations in medical treatment in recent years. These drugs offer potential curative treatments for severe or previously fatal diseases. In this article, I will explain features and challenges in…

By Izuru Ando

The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA